Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission

Clinical Endocrinology

Volumn 75, Issue 3, 2011, Pages 354-360

  Giordano, Roberta ^a   Picu, Andreea ^b   Marinazzo, Elisa ^b   D'Angelo, Valentina ^b   Berardelli, Rita ^b   Karamouzis, Ioannis ^b   Forno, Daniela ^a   Zinnà, Domenico ^b   MacCario, Mauro ^b   Ghigo, Ezio ^b   Arvat, Emanuela ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADRENAL CORTEX ADENOMA; ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CUSHING SYNDROME; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DYSLIPIDEMIA; FASTING GLUCOSE; FEMALE; HUMAN; HYPERCORTISOLISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; FASTING; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; LINEAR MODELS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PITUITARY ACTH HYPERSECRETION; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE;

EID: 79961239249     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04055.x     Document Type: Article

References (26)

1. Arnaldi, G., Angeli, A., Atkinson, A.B., et al. (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 88, 5593-5602. (Pubitemid 38033020)
2. Newell-Price, J., Bertagna, X., Grossman, A.B., et al. (2006) Cushing's syndrome. Lancet, 367, 1605-1617. (Pubitemid 43674231)
3. Nieman, L.K., Biller, B.M., Findling, J.W., et al. (2008) The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 93, 1526-1540. (Pubitemid 351656485)
4. Grundy, S.M., Cleeman, J.I., Daniels, S.R., et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735-2752. (Pubitemid 41532612)
5. Etxabe, J., &, Vazquez, J.A., (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology (Oxford), 40, 479-484. (Pubitemid 24194645)
6. Lindholm, J., Juul, S., Jørgensen, J.O., et al. (2001) Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism, 86, 117-123. (Pubitemid 32111743)
7. Mancini, T., Kola, B., Mantero, F., et al. (2004) High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology (Oxford), 61, 768-777. (Pubitemid 40006799)
8. Colao, A., Pivonello, R., Spiezia, S., et al. (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. The Journal of Clinical Endocrinology and Metabolism, 84, 2664-2672. (Pubitemid 30641990)
9. Faggiano, A., Pivonello, R., Spiezia, S., et al. (2003) Cardiovascular risk factors and common carotid artery calibre and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. Journal of Clinical Endocrinology and Metabolism, 88, 2527-2533. (Pubitemid 36724418)
10. Barahona, M.J., Sucunza, N., Resmini, E., et al. (2009) Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 94, 3365-3371.
11. Resmini, E., Farkas, C., Murillo, B., et al. (2010) Body composition after endogenous (Cushing's syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids. Hormone and Metabolic Research, 42, 613-618.
12. Webb, S.M., Mo, D., Lamberts, S.W., et al. (2010) Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous Cushing's disease or non-functioning pituitary adenoma. Journal of Clinical Endocrinology and Metabolism, 95, 630-638.
13. Whitworth, J.A., (2003) World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension, 21, 1983-1992. (Pubitemid 38296854)
14. American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care, 31, S55-S60.
15. Nelder, J.A., (1974) A user's guide to the evaluation of statistical packages and systems. International Statistical Review, 42, 291-298.
16. Andrews, R.C., &, Walker, B.R., (1999) Glucocorticoids and insulin resistance: old hormones, new targets. Clinical Science, 96, 513-523. (Pubitemid 29237902)
17. Arnaldi, G., Scandali, V.M., Trementino, L., et al. (2010) Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology, 92 (Suppl. 1), 86-90.
18. MacMahon, S., Peto, R., Cutler, J., et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335, 765-774. (Pubitemid 20106689)
19. Sleight, P., Yusuf, S., Pogue, J., et al. (2001) Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet, 358, 2130-2131. (Pubitemid 34094907)
20. Pirlich, M., Biering, H., Gerl, H., et al. (2002) Loss of body cell mass in Cushing's syndrome: effect of treatment. Journal of Clinical Endocrinology and Metabolism, 87, 1078-1084. (Pubitemid 36121069)
21. Ueland, T., Kristo, C., Godang, K., et al. (2003) Interleukin-1 receptor antagonist is associated with fat distribution in endogenous Cushing's syndrome: a longitudinal study. Journal of Clincal Endocrinology and Metabolism, 88, 1492-1496. (Pubitemid 36623359)
22. Tomlinson, J.W., Walker, E.A., Bujalska, I.J., et al. (2004) 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews, 25, 831-866. (Pubitemid 39366049)
23. Cooper, M.S., &, Stewart, P.M., (2009) 11beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Journal of Clinical Endocrinology and Metabolism, 94, 4645-4654.
24. Filipsson, H., Monson, J.P., Koltowska-Häggström, M., et al. (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism, 91, 3954-3961. (Pubitemid 44536870)
25. Terzolo, M., Pia, A., Alì, A., et al. (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? Journal of Clinical Endocrinology and Metabolism, 87, 998-1003. (Pubitemid 36121054)
26. Tsagarakis, S., Vassiliadi, D., &, Thalassinos, N., (2006) Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. Journal of Endocrinological Investigation, 29, 471-482. (Pubitemid 44043366)